Supernus Pharmaceuticals

SUPN · Nasdaq · United States

Share price · SUPN

$28.96-20.07 (-40.93%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.7M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SUPN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-32.8%
  2. 14 Oct 2026-4.4%

    Nothing announced by SUPN that day or the session before.

  3. 5 Aug 2026+8.5%
  4. 4 Aug 2026-6.0%
  5. 9 Jul 2026-3.4%

    Nothing announced by SUPN that day or the session before.

  6. 8 Jul 2026+5.2%
  7. 11 May 2026-4.2%
  8. 25 Feb 2026+5.7%
  9. 24 Feb 2026+5.1%
  10. 18 Feb 2026-2.8%

Share of unusual movement by asset

For each asset, the share of SUPN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Apomorphine (Apokyn) (Apokyn)
events and moves
5shown from 8 days
viloxazine (Qelbree)
events and moves
4shown from 8 days
Apomorphine (Onapgo) (Onapgo)
events and moves
3shown from 8 days
SPN-820
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—64%
Sessions with no dated event—33%

Assets

(10 total)
10Total Assets
7Approved
0Phase 3 / Filed
3Phase 1–2 / Early
7Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
Approved
NMDA receptorSmall molecule
Parkinson's Disease
Approved
Dopamine receptor (non-ergoline agonist)Small molecule
Parkinson's Disease
Approved
Dopamine receptor (non-ergoline agonist)Small molecule
Parkinson's Disease
Approved
Voltage-gated sodium channelSmall molecule
Epilepsy
Focal Onset Seizures
Safinamide(Xadago)
Approved
MAO-BSmall molecule
Parkinson's Disease
Approved
Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseSmall molecule
EpilepsyMigraineLennox-Gastaut Syndrome
Primary Generalized Tonic-Clonic Seizures
viloxazine(Qelbree)
Approved
norepinephrine transporterSmall molecule
Attention Deficit Hyperactivity Disorder
Phase 2
AcetylcholinesteraseSmall molecule
EpilepsyDravet Syndrome
Phase 2
mTORC1Small molecule
Major Depressive Disorder
Phase 2
mTORC1 (mammalian target of rapamycin complex 1) (activator)Small molecule
Major Depressive Disorder

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
viloxazine · QelbreePhase 3Attention-Deficit/Hyperactivity Disorder
Est. primary completion 2026-12 · NCT02736656 · CT.gov ↗
What to watch
Huperzine A (SPN-817)Phase 1/2Focal Impaired Awareness Seizures
Est. primary completion 2026-12-30 · NCT03474770 · CT.gov ↗
What to watch
SPN-821Phase 2Major Depressive Disorder (MDD)
Est. primary completion 2026-12-31 · NCT07226661 · CT.gov ↗
What to watch
2027 (3)
August 2027 (1)
Huperzine A (SPN-817)Phase 2Focal Onset Seizures
Est. primary completion 2027-08 · NCT06798896 · CT.gov ↗
What to watch
December 2027 (2)
Huperzine A (SPN-817)Phase 2Focal Onset Seizures
Est. primary completion 2027-12-31 · NCT07141329 · CT.gov ↗
What to watch
Huperzine A (SPN-817)Phase 2Epilepsy, Seizures, Epileptic
Est. primary completion 2027-12-31 · NCT05518578 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

February 2025Topline resultSPN-820Phase 2b in treatment-resistant depression did not meet its primary or secondary endpoints

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$227M$26M$177M+ $184M short-term inv.—$6.6M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$219M$29M$181M+ $192M short-term inv.$58M-$4.8M operating cash flowreport ↗
2026-Q1$208M$39M$186M+ $199M short-term inv.$2.3M$67M operating cash flowreport ↗
2025-Q3$192M$29M$153M+ $130M short-term inv.$45M-$62M operating cash flowreport ↗
2025-Q2$165M$22M$145M+ $378M short-term inv.—$59M operating cash flowreport ↗
2025-Q1$150M$27M$116M+ $348M short-term inv.$12M$31M operating cash flowreport ↗
2024-Q4——$319M+ $1.0M short-term inv.—-$17M operating cash flowreport ↗
2024-Q3$176M$29M$32M+ $372M short-term inv.—$54M operating cash flowreport ↗
2024-Q2$168M$26M$52M+ $295M short-term inv.—$36M operating cash flowreport ↗
2024-Q1$144M$25M$63M+ $234M short-term inv.—$38M operating cash flowreport ↗
2023-Q3$154M$23M$95M+ $105M short-term inv.$16M$36M operating cash flowreport ↗
2023-Q2$136M$24M$25M+ $127M short-term inv.$0.8M-$19M operating cash flowreport ↗
2023-Q1$154M$21M$462M+ $170M short-term inv.—$49M operating cash flowreport ↗
2022-Q3$177M$20M$111M+ $280M short-term inv.—$14M operating cash flowreport ↗
2022-Q2$170M$16M$173M+ $187M short-term inv.—$71M operating cash flowreport ↗
2022-Q1$153M$21M$116M+ $196M short-term inv.—$4.3M operating cash flowreport ↗
2021-Q3$148M$20M$215M+ $229M short-term inv.—-$4.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$719M$106M$130M+ $180M short-term inv.$9.6M$47M operating cash flowreport ↗

Supernus reported full-year 2025 revenue of $718.95M, up 8.6% YoY, with R&D spend of $106.24M, down 2.4% YoY. Cash, cash equivalents and current marketable securities were $308.7M at December 31, 2025, and the company reported a full-year net loss of $38.55M, with diluted loss per share of $0.68.

Management issued full-year 2026 guidance of $840M–$870M total revenues, $0–$30M operating earnings, and $140M–$170M adjusted operating earnings (non-GAAP). Clinically, the Phase 2b trial of SPN-817 for treatment-resistant focal seizures is ongoing, a follow-on Phase 2b trial of SPN-820 in major depressive disorder was initiated, and a Phase 1 study of SPN-443 is expected in the second half of 2026. Supernus also resumed new patient initiations for ONAPGO in the first quarter of 2026 after securing additional supply, following the product’s 2025 U.S. launch and the Sage Therapeutics acquisition.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$662M$109M$69M+ $384M short-term inv.—$172M operating cash flowreport ↗
2023-FY$608M$92M$75M+ $180M short-term inv.—$111M operating cash flowreport ↗
2022-FY$667M$75M$93M+ $368M short-term inv.—$117M operating cash flowreport ↗
2021-FY$580M$90M$203M+ $136M short-term inv.—$127M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 20 sales ($10.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Sensenig Bethany · directorOther (see filing) (derivative)24,153——Form 4
2026-11-02Hudson Frederick M. · directorOther (see filing)60,413——Form 4
2026-11-02NEWHALL CHARLES W III · directorOther (see filing)124,119——Form 4
2026-11-02Mottola Frank · SVP, Chief Tech. Ops. OfficerOther (see filing)19,544——Form 4
2026-11-02Rubin Jonathan · SVP, Chief Medical OfficerOther (see filing)13,979——Form 4
2026-11-02Bhatt Padmanabh P. · Sr. VP of IP, CSOOther (see filing)18,637——Form 4
2026-11-02Barlow Carrolee · directorOther (see filing)27,045——Form 4
2026-11-02DEC TIMOTHY C · Senior Vice-President & CFOOther (see filing)9,129——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 325 reporting institutions held 58.2M shares ($2.9B, 49.3% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.8,797,254$454.7M
2MILLENNIUM MANAGEMENT LLC3,315,973$171.4M
3VANGUARD PORTFOLIO MANAGEMENT LLC3,238,693$167.4M
4VANGUARD CAPITAL MANAGEMENT LLC2,467,215$127.5M
5DIMENSIONAL FUND ADVISORS LP2,307,030$119.2M
6STATE STREET CORP2,288,127$118.3M
7NOMURA ASSET MANAGEMENT INTERNATIONAL INC.2,037,202$105.3M
8ARMISTICE CAPITAL, LLC1,895,347$98.0M
9RENAISSANCE TECHNOLOGIES LLC1,705,222$88.1M
10GEODE CAPITAL MANAGEMENT, LLC1,623,514$83.9M
11CITADEL ADVISORS LLC1,493,446$77.2M
12LOOMIS SAYLES & CO L P1,425,779$73.7M
13Stephens Investment Management Group LLC1,351,331$69.9M
14Point72 Asset Management, L.P.1,318,555$68.2M
15Sofinnova Investments, Inc.954,309$49.3M